CD38 and AL amyloidosis: With the introduction of the anti-CD38 monoclonal antibody (daratumumab)-based combination regimen in the front-line setting, significant improvements in hematologic complete response (CR), organ responses [20,21], and potentially enhanced OS have been realized for AL amyloidosis patients.